2023年08月24日 21時00分

Source: China Medical System Holdings Ltd.

China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug

l Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The Product has a clear mechanism of action, which is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke depression.

l The product will enrich the cardio-cerebrovascular (including the central nervous system) pipeline of the Group. After approved for marketing in China, it is expected to meet the clinical needs of drug with both safety and efficacy, providing new treatment options to ischemic stroke patients in China.

SHENZHEN, CHINA, Aug 24, 2023 - (ACN Newswire) - On August 24, China Medical System Holdings Limited ("CMS" or the "Group") announced that the Group entered into a Collaboration Agreement (the "Agreement") with Nanjing NeuroDawn Pharmaceutical Co. Ltd. ("NeuroDawn Pharmaceutical"), for anti-ischemic stroke brain cytoprotectant and class 1 innovative drug Y-3 injection ("Y-3 injection" or the "Product"), and gained an exclusive promotion right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of the Agreement is permanent.

Y-3 Injection is a Class 1 innovative drug - small molecule compound, which is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The mechanism of action of the Product is to dissociate PSD-95 and nNOS coupling and activate α2-GABAA receptors. With dual-target intervention at the same time and its clear mechanism of action, the Product is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke depression.

Stroke is a major non-communicable disease that seriously endangers the health of Chinese people. The overall lifetime risk of stroke in China is 39.9%, ranking the first in the world. The number of new cases of ischemic stroke in China was approximately 2.87 million in 2019, and the incidence rate substantially increased by 226.5% from 1990 to 2019, with a large patient population. Stroke has the characteristics of high disability rate and heavy economic burden. There is an urgent clinical need for evidence-based drugs to reduce family and social burdens.

In January 2023, The Phase I clinical trial of the Product in China has been completed and the results showed a good overall safety. The Product is currently in the Phase II clinical trial in China. If approved for marketing in China, it will bring new treatment options to ischemic stroke patients in China, meet the clinical needs of drug with both safety and efficacy, and thus benefit the patients.

CMS has been deeply engaged in the cardio-cerebrovascula/central nervous system therapeutic fields for years and possesses XinHuoSu (recombinant human brain natriuretic peptide for injection), Deanxit (flupentixol and melitracen tablets) and VALTOCO (the first diazepam nasal spray approved in China), etc. The Group has also established a compliant and efficient commercialization system in the cardio-cerebrovascular and central nervous system fields. In the future, the Group will continue to prioritize patients and clinical needs, strategically deploy more differentiated innovative drugs, and consistently expand the product portfolio in the Group's advantageous specialty fields, benefiting a greater number of patients.

For further detailed information, please visit the following link for the announcement, "Voluntary and Business Update Announcement Gaining Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug" issued by CMS on August 24 2023.

About NEURODAWN PHARMACEUTICAL

NeuroDawn Pharmaceutical, based in Nanjing, China, is an innovation and R&D-driven new drug company, focusing on the research and development of new drugs for central nervous system (CNS) diseases. NeuroDawn Pharmaceutical has established a comprehensive internal R&D platform, including chemical synthesis, biological screening, CMC (chemistry, manufacturing and control) development, DMPK (drug metabolism and pharmacokinetics) research, in vivo pharmacology research, toxicology research and clinical research, etc. In addition, NeuroDawn Pharmaceutical has integrated clinical resources for neurological diseases in China and established close collaboration with more than one hundred leading hospitals in China to provide comprehensive and complete technical services and professional guidance for clinical studies.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs.

CMS focuses on developing first- or best-in-class innovative products and has made the layout of about 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

Source: China Medical System Holdings Ltd.
セクター: ヘルスケア, メドテック

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

関連プレスリリース


CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
2024年04月01日 21時30分
 
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
2024年03月28日 11時29分
 
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
2024年02月04日 10時00分
 
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
2024年01月02日 15時00分
 
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
2023年12月13日 18時36分
 
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
2023年07月31日 21時00分
 
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
2023年06月12日 21時00分
 
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
2023年05月30日 23時00分
 
CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
2022年08月26日 19時00分
 
もっと見る >>

新着プレスリリース


もっと見る >>